# Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

> **NCT03834883** · PHASE4 · COMPLETED · sponsor: **Indiana University** · enrollment: 27 (actual)

## Conditions studied

- Long QT Syndrome
- Abnormalities, Drug-Induced

## Interventions

- **DRUG:** Progesterone
- **DRUG:** Ibutilide

## Key facts

- **NCT ID:** NCT03834883
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-26
- **Primary completion:** 2024-05-21
- **Final completion:** 2024-05-23
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-07-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03834883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03834883, "Reducing the Risk of Drug-Induced QT Interval Lengthening in Women". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03834883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*